BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36038322)

  • 21. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-Eluting Microsphere Versus Cisplatin-Based Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Propensity Score-Matched Analysis.
    Chu HH; Gwon DI; Kim JH; Ko GY; Shin JH; Yoon HK
    AJR Am J Roentgenol; 2020 Sep; 215(3):745-752. PubMed ID: 32569514
    [No Abstract]   [Full Text] [Related]  

  • 23. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Guo W; Chen S; Wu Z; Zhuang W; Yang J
    Technol Cancer Res Treat; 2020; 19():1533033820965587. PubMed ID: 33089769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of drug-eluting bead-transcatheter arterial chemoembolization using 100-300 μm versus 300-500 μm CalliSpheres microspheres in patients with advanced-stage hepatocellular carcinoma.
    Yang T; Qin W; Sun X; Wang Y; Wu J; Li Z; Ji F; Zhang L; Liu W
    J Cancer Res Ther; 2020; 16(7):1582-1587. PubMed ID: 33565503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?
    Lee SY; Ou HY; Yu CY; Huang TL; Tsang LL; Cheng YF
    Diagn Interv Radiol; 2020 May; 26(3):230-235. PubMed ID: 32352922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver chemoembolization of hepatocellular carcinoma using TANDEM
    Delicque J; Guiu B; Boulin M; Schwanz H; Piron L; Cassinotto C
    Future Oncol; 2018 Nov; 14(26):2761-2772. PubMed ID: 29953255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
    Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
    J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
    Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
    World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Lyu T; Yao H; Wang J; Song L; Tong X; Zou Y
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101819. PubMed ID: 34619365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
    He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
    J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
    Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
    Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A; Hori S
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
    Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
    Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.